Press Releases

Date Title
September 16, 2015
Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer
Oncobiologics, Inc. announced the appointment of Lawrence A. Kenyon as its Chief Financial Officer (CFO), effective September 15, 2015. Mr. Kenyon is an accomplished executive with extensive experience managing the financial and business operations of emerging and established private and public
July 27, 2015
Oncobiologics Secures $31 Million Financing
Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing.  Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs.
July 2, 2015
Noted Immunology Expert Joins Oncobiologics as Chief Medical Officer
June 2015 - Cranbury, New Jersey — Kenneth Bahrt, MD, FACR has joined Oncobiologics as its Chief Medical Officer.  A recognized expert in immunology, he brings over 30 years of clinical and pharmaceutical industry experience in both small molecule and protein therapeutics.    Oncobiologics Founder
May 4, 2015
Oncobiologics opens commercial launch manufacturing facility
Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing monoclonal antibody (mAb) biosimilars,has completed the construction of its GMP commercial launch manufacturing facility at its headquarters in Cranbury, New Jersey.
April 15, 2015
Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidate
Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study.  This study is
February 12, 2015
ONS-3010 (Humira®/adalimumab biosimilar) meets primary endpoints in first clinical study
Cranbury, NJ – February 12, 2015 — Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars,announced today that ONS-3010, its adalimumab (Humira®) biosimilar candidate met the primary endpoints in its first clinical study.
October 7, 2014
Oncobiologics Appoints Dr. Todd C. Brady to its Board of Directors
Cranbury, NJ  -- October 7, 2014 – Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors.
July 16, 2014
Strides Arcolab makes strategic investment in Oncobiologics
July 16, 2014:  Cranbury, NJ  Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc, a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.
June 26, 2014
Liomont and Oncobiologics partner to launch Biosimilars in Mexico
Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market.  The scope of the agreement includes exclusive
June 12, 2014
Oncobiologics launches Phase I Clinical Trial for ONS-3010 Biosimilar version of Humira®
Cranbury, NJ – June 12, 2014 — Oncobiologics, Inc. announced today that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira®. After reviewing Oncobiologics’ Clinical Trial
Displaying 81 - 90 of 92